Cardiovascular Disease Doctors in Lake Havasu City, AZ Accepting Medicare

3 Cardiovascular Disease doctors found. Showing 1 - 3

Edward J Quinn, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 150 Riviera Dr, Lake Havasu City, AZ 86403 Phone: 928-855-5090

Dr. Kanaan Abow Alkhier, MD, RPVI, RCS, RVS Internal Medicine - Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 2082 Mesquite Ave, Lake Havasu City, AZ 86403 Phone: 928-453-2727

Fadi Atassi, MD Internal Medicine - Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 2082 Mesquite Ave, Suite A100, Lake Havasu City, AZ 86403 Phone: 928-453-2727    Fax: 928-453-2828

News Archive

Bristol-Myers Squibb divests its majority stake in Mead Johnson Nutritional

Bristol-Myers Squibb (New York, New York) is divesting its 83% majority stake in its last non-biopharmaceutical holding, Mead Johnson Nutritional (Evansville, Indiana).

Research suggests New York City may have reached coronavirus herd immunity threshold

A new study by researchers at University of Illinois at Urbana-Champaign and Brookhaven National Laboratory and published on the preprint server medRxiv in July 2020 discusses the effect of a factor called persistent contact heterogeneity on the final epidemic size of COVID-19.

Local efforts seek to reduce childhood obesity; Sleep-deprived kids most vulnerable

NPR: "[A] new study finds that even for infants and preschoolers, a good, long night's sleep may be just as important as diet and physical activity. Over the past three decades, obesity rates have doubled among children age 2 to 5, and tripled among 6- to 11-year-olds. So University of Washington maternal and child health researcher Janice Bell wanted to know whether sleep had anything to do with it.

Savient's KRYSTEXXA receives FDA approval for chronic gout in adult patients refractory to conventional therapy

Savient Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA™ (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated.

Read more Medical News

› Verified 7 days ago